Hormone Immunoassay Interference : A 2021 Update
Immunoassays are powerful qualitative and quantitative analytical techniques. Since the first description of an immunoassay method in 1959, advances have been made in assay designs and analytical characteristics, opening the door for their widespread implementation in clinical laboratories. Clinical endocrinology is closely linked to laboratory medicine because hormone quantification is important for the diagnosis, treatment, and prognosis of endocrine disorders. Several interferences in immunoassays have been identified through the years; although some are no longer encountered in daily practice, cross-reaction, heterophile antibodies, biotin, and anti-analyte antibodies still cause problems. Newer interferences are also emerging with the development of new therapies. The interfering substance may be exogenous (e.g., a drug or substance absorbed by the patient) or endogenous (e.g., antibodies produced by the patient), and the bias caused by interference can be positive or negative. The consequences of interference can be deleterious when clinicians consider erroneous results to establish a diagnosis, leading to unnecessary explorations or inappropriate treatments. Clinical laboratories and manufacturers continue to investigate methods for the detection, elimination, and prevention of interferences. However, no system is completely devoid of such incidents. In this review, we focus on the analytical interferences encountered in daily practice and possible solutions for their detection or elimination.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Annals of laboratory medicine - 42(2022), 1 vom: 01. Jan., Seite 3-23 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ghazal, Khaldoun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6SO6U10H04 |
|---|
| Anmerkungen: |
Date Completed 17.09.2021 Date Revised 02.01.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3343/alm.2022.42.1.3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329184245 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329184245 | ||
| 003 | DE-627 | ||
| 005 | 20231226203422.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3343/alm.2022.42.1.3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1097.xml |
| 035 | |a (DE-627)NLM329184245 | ||
| 035 | |a (NLM)34374345 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghazal, Khaldoun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hormone Immunoassay Interference |b A 2021 Update |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.09.2021 | ||
| 500 | |a Date Revised 02.01.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Immunoassays are powerful qualitative and quantitative analytical techniques. Since the first description of an immunoassay method in 1959, advances have been made in assay designs and analytical characteristics, opening the door for their widespread implementation in clinical laboratories. Clinical endocrinology is closely linked to laboratory medicine because hormone quantification is important for the diagnosis, treatment, and prognosis of endocrine disorders. Several interferences in immunoassays have been identified through the years; although some are no longer encountered in daily practice, cross-reaction, heterophile antibodies, biotin, and anti-analyte antibodies still cause problems. Newer interferences are also emerging with the development of new therapies. The interfering substance may be exogenous (e.g., a drug or substance absorbed by the patient) or endogenous (e.g., antibodies produced by the patient), and the bias caused by interference can be positive or negative. The consequences of interference can be deleterious when clinicians consider erroneous results to establish a diagnosis, leading to unnecessary explorations or inappropriate treatments. Clinical laboratories and manufacturers continue to investigate methods for the detection, elimination, and prevention of interferences. However, no system is completely devoid of such incidents. In this review, we focus on the analytical interferences encountered in daily practice and possible solutions for their detection or elimination | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Biotin | |
| 650 | 4 | |a Heterophile antibodies | |
| 650 | 4 | |a Hormone | |
| 650 | 4 | |a Immunoassay | |
| 650 | 4 | |a Interference | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 650 | 7 | |a Hormones |2 NLM | |
| 650 | 7 | |a Biotin |2 NLM | |
| 650 | 7 | |a 6SO6U10H04 |2 NLM | |
| 700 | 1 | |a Brabant, Severine |e verfasserin |4 aut | |
| 700 | 1 | |a Prie, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Piketty, Marie-Liesse |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of laboratory medicine |d 2012 |g 42(2022), 1 vom: 01. Jan., Seite 3-23 |w (DE-627)NLM215937082 |x 2234-3814 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2022 |g number:1 |g day:01 |g month:01 |g pages:3-23 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3343/alm.2022.42.1.3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2022 |e 1 |b 01 |c 01 |h 3-23 | ||